← Patent-cliff monitor small molecule XPHOZAH TENAPANOR HYDROCHLORIDE
Loss of exclusivity November 2042 latest FDA-listed patent expiry
Company Ardelyx → See this company's full patent-cliff portfolio Drug detail Brand name XPHOZAH Active ingredient TENAPANOR HYDROCHLORIDE Strength EQ 20MG BASE Dosage form TABLET Route ORAL Modality Small molecule FDA approval October 2023 Marketing status RX
Listed patents Patent Expires Type 12539299 November 2042 product 10940146 April 2034 use U-381 10272079 April 2034 use U-381 8541448 August 2033 substance, product 8969377 December 2029 substance, product 12016856 December 2029 substance, product
Regulatory exclusivity Code Expires NP October 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.